Connecting via Winsock to STN

Welcome to STN International!  Enter x:x

LOGINID:SSPTAEGS1646

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * *  Welcome to STN International  * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS 2 | APR 04 | STN AnaVist, Version 1, to be discontinued |
| NEWS 3 | APR 15 | WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats |
| NEWS 4 | APR 28 | EMBASE Controlled Term thesaurus enhanced |
| NEWS 5 | APR 28 | IMSRESEARCH reloaded with enhancements |
| NEWS 6 | MAY 30 | INPAFAMDB now available on STN for patent family searching |
| NEWS 7 | MAY 30 | DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option |
| NEWS 8 | JUN 06 | EPFULL enhanced with 260,000 English abstracts |
| NEWS 9 | JUN 06 | KOREAPAT updated with 41,000 documents |
| NEWS 10 | JUN 13 | USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications |
| NEWS 11 | JUN 19 | CAS REGISTRY includes selected substances from web-based collections |
| NEWS 12 | JUN 25 | CA/CAplus and USPAT databases updated with IPC reclassification data |
| NEWS 13 | JUN 30 | AEROSPACE enhanced with more than 1 million U.S. patent records |
| NEWS 14 | JUN 30 | EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations |
| NEWS 15 | JUN 30 | STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in |
| NEWS 16 | JUN 30 | STN AnaVist enhanced with database content from EPFULL |
| NEWS 17 | JUL 28 | CA/CAplus patent coverage enhanced |
| NEWS 18 | JUL 28 | EPFULL enhanced with additional legal status information from the epoline Register |
| NEWS 19 | JUL 28 | IFICDB, IFIPAT, and IFIUDB reloaded with enhancements |
| NEWS 20 | JUL 28 | STN Viewer performance improved |
| NEWS 21 | AUG 01 | INPADOCDB and INPAFAMDB coverage enhanced |
| NEWS 22 | AUG 13 | CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998 |
| NEWS 23 | AUG 15 | CAOLD to be discontinued on December 31, 2008 |
| NEWS 24 | AUG 15 | CAplus currency for Korean patents enhanced |
| NEWS 25 | AUG 25 | CA/CAplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching |
| NEWS 26 | AUG 27 | CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information |

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS  STN Operating Hours Plus Help Desk Availability

```
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:14:49 ON 04 SEP 2008

=> FILE .Gerry2MBCE
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'MEDLINE' ENTERED AT 16:15:11 ON 04 SEP 2008

FILE 'BIOSIS' ENTERED AT 16:15:11 ON 04 SEP 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 16:15:11 ON 04 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 16:15:11 ON 04 SEP 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

=> S (Nishikawa OR Nakagami OR Kaneda) AND VEGF AND pd<=20050317
   2 FILES SEARCHED...
L1           2 (NISHIKAWA OR NAKAGAMI OR KANEDA) AND VEGF AND PD<=20050317

=> Dup Rem L1
PROCESSING COMPLETED FOR L1
L2            2 DUP REM L1 (0 DUPLICATES REMOVED)
                ANSWER '1' FROM FILE BIOSIS
                ANSWER '2' FROM FILE CAPLUS

=> D Ibib ABS  L2 1-2

L2   ANSWER 1 OF 2  BIOSIS  COPYRIGHT (c) 2008 The Thomson Corporation  on STN
ACCESSION NUMBER:   2002:151865  BIOSIS
DOCUMENT NUMBER:    PREV200200151865
TITLE:              Post-natal CD34+KDR+ cells generate both hematopoietic and
                    endothelial cells in minibulk culture.
AUTHOR(S):          Pelosi, Elvira; Valtieri, Mauro [Reprint author]; Sgadari,
                    Cecilia; Coppola, Simona; Testa, Ugo; Peschle, Cesare
                    [Reprint author]
CORPORATE SOURCE:   Kimmel Cancer Center, T. Jefferson University,
                    Philadelphia, PA, USA
SOURCE:             Blood, (November 16, 2001) Vol. 98, No. 11 Part
                    2, pp. 124b. print.
                    Meeting Info.: 43rd Annual Meeting of the American Society
                    of Hematology, Part 2. Orlando, Florida, USA. December
                    07-11, 2001. American Society of Hematology.
                    CODEN: BLOOAW. ISSN: 0006-4971.
```

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 21 Feb 2002
Last Updated on STN: 26 Feb 2002

AB The functional role of vascular endothelial growth factor receptor 2 (KDR in humans, Flk1 in mice) is well established for endothelial cells. In embryonic life Flk1+cells give rise to both hematopoietic and endothelial progeny (Nishikawa et al., Development, 1998). In post-natal life the CD34+KDR+ cell subset (ltoreq1.5% of the whole CD34+ population) exhibits hematopoietic stem cell activity (Ziegler et al., Science 1999), and contains endothelial precursors (Peichev et al., Blood, 2000). We have tested the capacity of cord blood CD34+KDR+ cells to generate hematopoietic and endothelial progeny in serum-free liquid suspension cultures. A total of 36 experiments were performed. The sorted CD34+KDR+ cells (KDR1/KDR2 MoAbs, see Botta et al., ASH 2001) were seeded in the culture wells (apprx2,000-4,000 cells/0.2 ml) supplemented with VEGF at saturating level. Control cultures were seeded with CD34+KDR- cells. In all experiments we observed that, after 1-2 wk, all CD34+KDR- cells were dead. Conversely, 30-70% of CD34+KDR+ cells survived (this residual population, composed of small blast cells, is highly-enriched for 12-wk long-term culture initiating cells, see Ziegler et al, Science, 1999). At later culture times, the blast cell population persisted and gradually generated a progeny of larger cells for up to 6 months. The cells were analyzed at sequential culture times by morphology, immunofluorescence, immunohistochemistry and RT-PCR analysis. The small blasts were CD45dim or CD45-, while negative for markers of differentiated hematopoietic and endothelial cells (particularly, CD14 and VW factor/VE-cadherin). The larger cells comprised three cell types: (a) monocytic/dendritic cells (CD45+14+, VW-) at different stages of differentiation/maturation; (b) endothelial cells (CD45-/14-, VW+VE-cadhein+) at sequential stages of development (from small mononucleated to large polynucleated cells); (c) a few, relatively small cells expressing both hematopoietic and endothelial markers, apparently bipotent for both lineages. These studies indicate that the CD34+KDR+ cell population comprises both hematopoietic and endothelial precursors, thus in line with similar results on in vitro differentiation of Flk1+cells from adult murine bone marrow (Huang et al., Bioch. Bioph. Res. Comm., 1999) Furthermore, we observed that few cells are bipotent for both linages: further studies were performed to verify whether these cells may hypothetically represent nemoangioblasts (see valtiere et al. Identification of nemoangioblast in post-natal CD34+KDR+ cells", ASH 2001).

L2 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:144611 CAPLUS
DOCUMENT NUMBER: 131:86128
TITLE: Vascular endothelial growth factor (VEGF) likely contributes to oligodendroglioma angiogenesis. Comments
AUTHOR(S): Christov, C.; Gherardi, R. K.
CORPORATE SOURCE: Department of Pathology (Neuropathology), Hospital Henri Mondor, Creteil, F-94010, Fr.
SOURCE: Acta Neuropathologica (1999), 97(4), 429-430
CODEN: ANPTAL; ISSN: 0001-6322
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A polemic in response to Nishikawa et al. (1998, Acta Neuropathol 96:453) reiterating that vascular endothelial growth factor is involved in vascular-endothelial proliferation in grade III oligodendrogliomas.

```
REFERENCE COUNT:          5     THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> S (Nishikawa OR Nakagami OR Kaneda) AND (Treatment (S) Ischem?) AND pd<=20050317
   1 FILES SEARCHED...
L3            0 (NISHIKAWA OR NAKAGAMI OR KANEDA) AND (TREATMENT (S) ISCHEM?)
                AND PD<=20050317

=> S (Nishikawa OR Nakagami OR Kaneda) AND Angiogen? AND pd<=20050317
   1 FILES SEARCHED...
L4            2 (NISHIKAWA OR NAKAGAMI OR KANEDA) AND ANGIOGEN? AND PD<=20050317

=> D Ibib ABS L4 1-2

L4   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         1999:144611  CAPLUS
DOCUMENT NUMBER:          131:86128
TITLE:                    Vascular endothelial growth factor (VEGF) likely
                          contributes to oligodendroglioma angiogenesis
                          . Comments
AUTHOR(S):                Christov, C.; Gherardi, R. K.
CORPORATE SOURCE:         Department of Pathology (Neuropathology), Hospital
                          Henri Mondor, Creteil, F-94010, Fr.
SOURCE:                   Acta Neuropathologica (1999), 97(4), 429-430
                          CODEN: ANPTAL; ISSN: 0001-6322
PUBLISHER:                Springer-Verlag
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
AB   A polemic in response to Nishikawa et al. (1998, Acta
     Neuropathol 96:453) reiterating that vascular endothelial growth factor is
     involved in vascular-endothelial proliferation in grade III
     oligodendrogliomas.
REFERENCE COUNT:          5     THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4   ANSWER 2 OF 2  EMBASE  COPYRIGHT (c) 2008 Elsevier B.V. All rights
     reserved on STN
ACCESSION NUMBER:    2003444071  EMBASE
TITLE:               Question and answer sessions with Dr. Shin-Ichi
                     Nishikawa.
AUTHOR:              Negi, Akira, Dr. (correspondence)
CORPORATE SOURCE:    Kobe Univ., Kobe, Japan.
AUTHOR:              Tamai, Makoto
CORPORATE SOURCE:    Tohoku Univ., Sendai, Japan.
AUTHOR:              Nishikawa; Noda
SOURCE:              Ophthalmologica, (2003) Vol. 217, No. SUPPL. 1,
                     pp. 43-44.
                     ISSN: 0030-3755  CODEN: OPHTAD
COUNTRY:             Switzerland
DOCUMENT TYPE:       Journal; Conference Article; (Conference paper)
FILE SEGMENT:        012     Ophthalmology
LANGUAGE:            English
ENTRY DATE:          Entered STN: 13 Nov 2003
                     Last Updated on STN: 13 Nov 2003


=> Log off H
 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:22:43 ON 04 SEP 2008
```